Heidelberg Pharma AG annual ebitda
2022
2023
2024
2025
Heidelberg Pharma AG EBITDA Growth & History (HPHA)
Heidelberg Pharma AG's calculated EBITDA was −€38.4M for fiscal 2025.
View full Heidelberg Pharma AG company overviewHeidelberg Pharma AG annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-11-30 | −€38.4M | −€20.0M | — |
| 2024 | 2024-11-30 | −€18.4M | €336,608 | — |
| 2023 | 2023-11-30 | −€18.7M | −€2.5M | — |
| 2022 | 2022-11-30 | −€16.2M | — | — |
Heidelberg Pharma AG quarterly ebitda
Q1.25
Q2.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-05-31 | €1.3M | €7.8M | — |
| Q1 2026 | 2026-02-28 | −€4.2M | €1.5M | — |
| Q4 2025 | 2025-11-30 | −€18.0M | — | — |
| Q2 2025 | 2025-05-31 | −€6.4M | — | — |
| Q1 2025 | 2025-02-28 | −€5.7M | — | — |
Heidelberg Pharma AG ebitda trends
Between the periods ended 2022-11-30 and 2025-11-30, Heidelberg Pharma AG's ebitda decreased from −€16.2M to −€38.4M, a change of −€22.2M. The latest reported quarter, Q2 2026, shows €1.3M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Heidelberg Pharma AG source filings ↗Community posts
Heidelberg Pharma reports early myeloma responses and selects a development dose
Heidelberg Pharma ($HPHA) presented Phase 1 results for pamlectabart tismanitin, its experimental antibody-drug conjugate for relapsed or refractory multiple myeloma. Among 31 evaluable patients in dose cohorts five through nine, 13 respond ...
